Humedix Overview
- Year Founded
-
2002
- Status
-
Public
- Employees
-
386
- Stock Symbol
-
200670
- Investments
-
6
- Share Price
-
$16.71
- (As of Friday Closing)
Humedix General Information
Description
Humedix Co Ltd is a cosmeceutical healthcare company. It supplies Hyaluronic Acid raw material medicine of low molecule and the high molecule which are used in arthritis medicine, eyedrops and in injections for ophthalmology. Further, it is dedicated to the development of new functional materials with diverse physiological activities including vitamin derivatives and supplies a variety of functional materials. In addition, it offers various medical devices, cosmetic and health functional foods. The business activities are primarily carried out through South Korea.
Contact Information
Website
www.humedix.comCorporate Office
- 6th Floor, HuonsGlobal Building, A-dong, Pangyo I-Square
- 17, Changeop-ro, Sujeong-gu
- Seongnam, Gyeonggi 13449
- South Korea
Corporate Office
- 6th Floor, HuonsGlobal Building, A-dong, Pangyo I-Square
- 17, Changeop-ro, Sujeong-gu
- Seongnam, Gyeonggi 13449
- South Korea
Humedix Stock Performance
As of 13-Nov-2026, Humedix’s stock price is $16.71. Its current market cap is $184M with 11M shares.
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $16.71 | $16.79 | $14.57 - $34.88 | $184M | 11M | 23.4K | $2.99 |
Humedix Financials Summary
As of 30-Jun-2026, Humedix has a trailing 12-month revenue of $123M.
|
In Thousands, USD |
TTM 30-Jun-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | 109,443 | 202,977 | 231,461 | 213,767 |
| Revenue | 122,567 | 119,492 | 118,637 | 116,466 |
| EBITDA | 44,308 | 49,631 | 41,250 | 32,400 |
| Net Income | 31,633 | 36,388 | 28,773 | 18,984 |
| Total Assets | 216,876 | 224,748 | 169,557 | 170,700 |
| Total Debt | 522 | 945 | 2,008 | 2,097 |
Humedix Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Humedix Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Humedix Patents
Humedix Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026141878-A1 | Gel composition for wound dressing comprising alloferon as active ingredient | Pending | 23-Dec-2024 | ||
| EP-4371587-A1 | Method for preparation of filler containing dna fraction and filler prepared thereby | Pending | 14-Jul-2021 | ||
| EP-4371587-A4 | Method for preparation of filler containing dna fraction and filler prepared thereby | Pending | 14-Jul-2021 | ||
| US-20230414475-A1 | Method for preparation of filler containing dna fraction and filler prepared thereby | Pending | 14-Jul-2021 | ||
| WO-2023287106-A1 | Method for preparation of filler containing dna fraction and filler prepared thereby | Inactive | 14-Jul-2021 | A61K8/606 |
Humedix Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Humedix Investments & Acquisitions (6)
Humedix’s most recent deal was a PIPE with DRTech for . The deal was made on 31-Dec-2025.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| DRTech | 31-Dec-2025 | PIPE | Diagnostic Equipment | ||
| L&C Bio | 31-Dec-2025 | PIPE | Diagnostic Equipment | ||
| Ensol Biosciences | 20-Feb-2023 | PIPE | Drug Discovery | ||
| Kineta | 04-Oct-2021 | Later Stage VC | Drug Discovery | ||
| Woori B&B | 01-Nov-2019 | Corporate | Biotechnology |
Humedix ESG
Risk Overview
Risk Rating
Updated April, 30, 2025
31.09 | High Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 14,271
Rank
Percentile
Pharmaceuticals
Industry
of 908
Rank
Percentile
Pharmaceuticals
Subindustry
of 406
Rank
Percentile
Humedix Exits (1)
Humedix’s most recent exit was on 04-Oct-2021 from Kineta. The exit was categorized as .
| Company Name | Exit Date | Exit Type | Exit Size | Status | Buyers |
|---|---|---|---|---|---|
| Kineta | 04-Oct-2021 | Completed |
|
Humedix FAQs
-
When was Humedix founded?
Humedix was founded in 2002.
-
Where is Humedix headquartered?
Humedix is headquartered in Seongnam, South Korea.
-
What is the size of Humedix?
Humedix has 386 total employees.
-
What industry is Humedix in?
Humedix’s primary industry is Pharmaceuticals.
-
Is Humedix a private or public company?
Humedix is a Public company.
-
What is Humedix’s stock symbol?
The ticker symbol for Humedix is 200670.
-
What is the current stock price of Humedix?
As of 13-Nov-2026 the stock price of Humedix is $16.71.
-
What is the current market cap of Humedix?
The current market capitalization of Humedix is $184M.
-
What is Humedix’s current revenue?
The trailing twelve month revenue for Humedix is $123M.
-
What is Humedix’s annual earnings per share (EPS)?
Humedix’s EPS for 12 months was $2.99.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
